Is there a new cure for Restless Legs Syndrome?
No, and it is worth hearing that plainly rather than a fourth round of hedging. Nothing published cures Restless Legs Syndrome, and nobody is close, because the underlying cause is still being argued over in the journals. What exists instead is a longer list of ways to quieten the symptoms.
The useful question is not “is there a cure” but “has the list changed since I last looked”. It has changed, and more than most people realise. If your information about Restless Legs is five years old, it is out of date in three specific ways, all covered below.
Being sold the word “cure” is its own particular experience, and it helps to know where it comes from. It turns up in headlines about early-stage research, in supplement marketing, and in forum posts from someone who had a good fortnight. None of those is a treatment tested against a placebo.
What actually changed: the first-choice medicines are no longer first choice
If you were put on a dopamine agonist years ago and it slowly stopped working, that was not you doing it wrong. It is a documented pattern, and the guidelines have now caught up with it. Your experience has a name, and there is a different medicine class to ask about instead.
The 2024 American Academy of Sleep Medicine guidelines (Winkelman et al., Journal of Clinical Sleep Medicine) make a conditional recommendation against routine ongoing use of the dopamine agonists, ropinirole and pramipexole. The reason is augmentation: symptoms creeping earlier into the day and worsening over months or years on the very drug meant to control them.
In Australia, pramipexole is sold as Sifrol. That is why plenty of people recognise the pattern long before they recognise the word for it.
There is something specific to ask for instead, which is what makes this useful rather than just annoying. Where medication is warranted, those same guidelines strongly recommend a different class: the alpha-2-delta ligands, meaning gabapentin enacarbil, gabapentin and pregabalin.
Being clear about what the guidelines did not say matters as much. They did not say drug therapy is finished for Restless Legs. They reordered it. If you take a prescription for this, none of the above is a reason to stop it on your own, and stopping a dopamine agonist abruptly can make the next few nights considerably worse.
Two things are worth reading if this is your situation. Our guide to Restless Legs medication side effects goes through the guideline change in full, and Sifrol and Restless Legs Syndrome covers the Australian brand specifically.
If your symptoms have crept earlier into the day, Restless Legs augmentation describes exactly what you are looking at. For what the guidelines now put ahead of it, read pramipexole alternatives.
What is the newest treatment for Restless Legs Syndrome?
Knowing which of the new options has real evidence behind it saves a lot of money and a lot of disappointment. Four things have moved since 2020, and they are not equally proven. The table below ranks them by the quality of the evidence rather than by how new they sound.
| Option | What it is | Evidence quality | Where it stands in 2026 |
|---|---|---|---|
| Alpha-2-delta ligands | Prescription tablets (gabapentin, pregabalin, gabapentin enacarbil) | Strong. Now the recommended first medication in the 2024 AASM guidelines | Available, prescription only, sedating for some people |
| Intravenous iron | An iron infusion when ferritin is low | Strong for the right patients. Guideline-recommended below a ferritin of 100 micrograms per litre | Available in Australia, needs a blood test and a referral |
| Nerve stimulation | A prescription device worn on the legs that stimulates a nerve near the knee | Moderate. One randomised sham-controlled crossover trial in 43 adults | Prescription device, availability outside the United States is limited |
| Targeted overnight compression | Pressure applied to the feet while you sleep, no drugs, no electronics | Moderate. One randomised sham-controlled trial and one single-arm study | Available as a wearable, no prescription needed |
One more sits below the line because it has not earned a row yet. Dipyridamole, an existing medicine used for something else entirely, produced a striking result in one small crossover trial. It is the most interesting genuinely new idea in the field, and it is not approved for Restless Legs anywhere.
The newer options, one at a time
Nerve stimulation devices
For people whose medication has stopped working, this is the option most likely to be new information. Buchfuhrer and colleagues (2021), in the Journal of Clinical Sleep Medicine, ran a randomised, participant-blinded crossover trial in 43 adults with moderate-to-severe Restless Legs.
Each person used both the real device and a sham for 14 nights. On the Clinical Global Impression of Improvement scale, 45 per cent responded to the device against 16 per cent on the sham.
What that number means in practice is worth spelling out, because 45 per cent is not 90 per cent. Roughly one in two people got a meaningful improvement and one in two did not. That is a normal result for a real treatment, and a far more believable one than most things marketed for this condition.
Getting hold of one in Australia is the catch. It is a prescription device and it is not widely available here, so a neurologist or sleep physician is the person to ask rather than a pharmacy.
If you are weighing up electrical approaches generally, our piece on TENS therapy for Restless Legs explains why a cheap TENS unit from the chemist is not the same thing.
Intravenous iron
An iron infusion is the closest thing to a fix that exists, for the specific group of people whose iron stores are low. The 2024 AASM guidelines recommend intravenous ferric carboxymaltose for adults with a ferritin under 100 micrograms per litre.
The reason so few people have had this conversation is a testing gap, not a treatment gap. A standard full blood count can read completely normal while ferritin sits low, and ferritin is not included unless somebody asks for it. Ask for the number, not the verdict.
Getting the test is the cheapest useful thing on this entire page. Our guide to iron, ferritin and Restless Legs covers what to ask for and what the number means.
The adenosine idea, and dipyridamole
This part of the research could change the picture within a decade, so it is worth knowing about even though you cannot act on it yet. Garcia-Borreguero and colleagues (2021), in Movement Disorders, ran a randomised, double-blind, placebo-controlled crossover study of dipyridamole in untreated adults.
Scores on the standard severity scale fell from 24.1 to 11.1 on the drug, against 23.7 to 18.7 on placebo. That is a large gap for a two-week study.
Holding that result loosely is the sensible response. Twenty-eight people is a very small trial, and one promising crossover study is where plenty of treatments have peaked and gone nowhere. Its real significance is that researchers are now interested in adenosine rather than dopamine as the thing that has gone wrong.
Weighted blankets, and why they keep coming up
Wanting something you can buy tonight, with no prescription attached, is completely reasonable. It is why weighted blankets get recommended constantly in Restless Legs groups, and the idea behind them is not silly, because pressure does appear to do something for this condition.
The problem is delivery. A weighted blanket applies pressure to all of you, unevenly, and slides off when you move. Moving is exactly what legs with Restless Legs do all night.
Deciding between the two is easier once you have seen them side by side. That is what weighted blankets versus compression for Restless Legs sets out, including what the pressure evidence supports and what it does not.
Targeted overnight compression
The reason pressure keeps appearing in this research is that it has been tested twice, properly, and it worked both times. Lettieri and Eliasson (2009), in Chest, ran a prospective, randomised, double-blinded, sham-controlled trial of pneumatic compression in 35 adults, 21 on the real device and 14 on a sham.
Symptom severity fell about 40 per cent, from 14.1 to 8.4 on the standard scale. Roughly a third reported complete relief, while nobody on the sham did.
The second study is more often quoted and more often misquoted. Kuhn and colleagues (2016), in the Journal of the American Osteopathic Association, followed 30 adults using targeted foot compression for eight weeks. Participants recorded a 90 per cent improvement on the Clinical Global Impression scale, against the 63 per cent published for ropinirole.
That study had no control group. The drug figure came from earlier separate trials rather than a comparison run at the same time, so it is not a head-to-head result and should not be described as one.
What that leaves is a real but modest evidence base, which is more than most non-drug options on the usual list can claim. Our review of the compression evidence sets out every published trial with its sample size and limitations.
If you are wondering whether the compression socks in the chemist would do, whether compression helps Restless Legs explains why they are a different product doing a different job.
Why “new cure” headlines keep letting people down
Getting your hopes up and then finding out it was a mouse study is a specific kind of tired, and it happens to people with this condition more than most. There are three reasons the headlines and the reality keep drifting apart.
The first is that early research gets reported as though it were finished. A crossover trial in 28 people is a reason for researchers to run a bigger trial. It is not a reason to change what you do tonight, and the gap between those two things is usually about ten years.
The second is that Restless Legs responds strongly to placebo, more than most conditions do. That is not a comment on anybody’s character. It is a measured effect, and it is precisely why the sham-controlled trials above carry weight and the testimonials do not.
The third is that “cure” is doing marketing work rather than describing anything. Supplements, magnets, oils and bars of soap under the sheets all get sold on that word. None has produced a sham-controlled result worth the name.
What to try if you want something different tonight
Having four things to work through beats having forty, particularly at the point in the evening when you are reading this. The order below is roughly the order of payoff, and the first two cost almost nothing.
- Get a ferritin test, not just an iron study. Ask for the number. Under 100 micrograms per litre puts an evidence-backed treatment on the table that most people never get offered.
- Audit what you are already taking. The 2024 AASM guidelines name antihistaminergic, serotonergic and antidopaminergic medicines, alcohol, caffeine and untreated sleep apnoea as exacerbating factors to deal with first. Several common antidepressants and over-the-counter sleep aids sit in that list. Never stop a prescribed medicine on your own.
- If you are on a dopamine agonist and it is getting worse, book the conversation. Augmentation is the most fixable thing in this whole article, and it needs a prescriber, not a new supplement.
- Sort out the hours you are actually asleep separately. Everything above happens while you are awake. Our guide to how to stop restless legs at night covers what is left once the daytime work is done.
For the non-medication options with the evidence behind each one, read drug-free Restless Legs treatment. If you are working out what is realistically available here rather than in an American forum, Restless Legs treatment in Australia goes through it.
What the research actually shows
Seeing the numbers with their limits attached tends to matter more to people who have been fobbed off before. Here is the evidence this article rests on, stated with what each study can and cannot support.
The guideline reversal. The 2024 American Academy of Sleep Medicine guidelines (Winkelman et al., Journal of Clinical Sleep Medicine) conditionally recommend against routine ongoing use of the dopamine agonists on augmentation grounds. They strongly recommend the alpha-2-delta ligands where medication is warranted, and intravenous ferric carboxymaltose below a ferritin of 100 micrograms per litre.
What those guidelines did not say. They named several medicines, alcohol, caffeine and untreated sleep apnoea as exacerbating factors to address first. They did not say drug therapy is off the table for Restless Legs.
Nerve stimulation. Buchfuhrer et al. (2021), in the Journal of Clinical Sleep Medicine, 17(8) 1685-1694, ran a randomised, participant-blinded crossover trial in 43 adults. Response on the Clinical Global Impression of Improvement scale was 45 per cent against 16 per cent on sham.
The adenosine idea. Garcia-Borreguero et al. (2021), in Movement Disorders, ran a two-week randomised, double-blind, placebo-controlled crossover study of dipyridamole in 28 adults. Severity scores fell from 24.1 to 11.1 on the drug against 23.7 to 18.7 on placebo. It is small, short, and not approved for this use.
Pneumatic compression. Lettieri and Eliasson (2009), in Chest, ran a prospective, randomised, double-blinded, sham-controlled trial in 35 adults, 21 therapeutic and 14 sham. Severity fell about 40 per cent, from 14.1 to 8.4, and roughly a third reported complete relief against none on sham.
Targeted foot compression. Kuhn et al. (2016), in the Journal of the American Osteopathic Association, followed 30 adults over eight weeks. Participants recorded a 90 per cent improvement on the Clinical Global Impression scale, against the 63 per cent published for ropinirole. The study had no control group, so that drug figure came from earlier separate trials.
What all of this adds up to is an honest picture rather than a triumphant one. There is no cure. There are four things with real trial evidence behind them, and most people with Restless Legs have been offered one of the four.
What Stillr is, and isn’t
Wanting one thing that is still working at 2am, without adding another tablet to the pile, is the whole reason Stillr exists. It is a drug-free compression sleeve worn overnight on both legs, designed in Australia: no batteries, no wires, nothing swallowed. It is a wellness product, not a medicine and not a cure. Stillr is pre-launch. It is AUD $169 a pair, in two sizes: Regular (AU women’s 5 to 8) and Large (AU women’s 8.5 to 11, men’s 7 to 10). Every pair carries a 60-Night Sleep Trial.
If you came here hoping for a cure, the honest answer is that there is not one, and you deserved to hear that from someone rather than work it out after another disappointing purchase. What there is, is a shorter list of things that have been tested properly. You can reserve your pair and join the founders’ list at stillr.com.au.